Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
about
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitorEmerging therapeutic options for the management of hepatitis C infectionConditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease ActivityComparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase InhibitorsSelected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignanciesEnhanced anti-HCV activity of interferon alpha 17 subtypeA multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsEvaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevirHepatitis C treatment: where are we now?Advances in the treatment of hepatitis C virus infectionVirologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirDevelopment of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingHepatitis C protease and polymerase inhibitors in developmentA viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Hepatitis C and kidney disease.Rapid emergence of protease inhibitor resistance in hepatitis C virus.Direct-acting antivirals for chronic hepatitis C.A perspective on modelling hepatitis C virus infection.Hepatitis C virus virology and new treatment targets.Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsHepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis.Current status and future directions in the management of chronic hepatitis C.Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitorDirect-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.In the clinic. Hepatitis C.Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Treatment of chronic hepatitis B: focus on telbivudine.Serine protease inhibitors as anti-hepatitis C virus agents.DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target.
P2860
Q24621496-61D9FE57-AA96-49B8-BC68-4C5773F98B80Q24650264-CB2AAAC0-7D84-40E4-9C04-C9B33FCD5DC8Q27012744-2077CB8C-037E-4135-9869-E0BAE6BE270AQ27318504-0041A4E8-3BEE-4E22-9CA9-00AE2C3C7ECDQ27486813-0A0E32B5-F2E0-44E6-B1B7-5BDB69AC8E8AQ27487389-0C6AE33B-1358-497D-9F45-67F8D2B5D8E3Q27487391-046C84CE-0D93-42B5-A9DB-F843260D97DFQ27487855-C3273BDE-CCA7-4B9B-A95E-D8A008466F84Q27488764-C1C79172-DF37-4E61-B78A-67BDCD9F1DD8Q28473678-A7A5BA51-775C-48D7-94BF-C45E88214188Q28481622-F5C9A38F-AFEA-45A6-AA93-6BB93C373975Q30378509-F3D1245E-7A03-4482-B28E-41945A42CA2EQ30415138-DB379BFF-2AE1-4A3B-8B06-0F536DE16CDCQ33648185-AD70CE15-4E64-4386-B17B-0659DA869948Q33826766-A6FD9BDF-254E-4B15-B370-D51BA38F780CQ33899320-E95A8BD4-C43A-4CF9-AEFC-848CB7AD4639Q34085348-2B8573D6-6E39-4A40-8D30-7CC5F8AC25C8Q34126254-93149F5B-91D5-4C8B-B537-E282144C18F0Q34172595-893D3057-EF91-4617-84BD-AA33BFFC7301Q34184046-DD0A123D-F1C1-4B5C-ACAB-B340E2A5307EQ34276394-8536314B-85B2-4B87-998D-C79DFB3F4544Q34409020-A9F6FC1B-6711-4CB5-8287-906282892997Q34415087-1E4DA6B0-026F-4484-8DF6-EFBE1DC0807FQ34551913-186C6F32-08D9-4041-86D3-561409B4BB74Q34557595-65141582-D2D7-47E4-BBDA-AD49387CCB51Q34759489-EEA51514-3B13-4551-A273-B9D94014393CQ34974042-45506FBA-469A-4ED0-A512-003068CC5A93Q35012057-B41B6DE5-467D-45B5-BDCF-F75C175550FEQ35026553-882D3522-2519-4459-8DBA-C50BD9FCC66BQ35610571-9550B982-2231-4F5E-BBA0-341D0EB9D4AAQ35839723-1688CC2E-05F4-42A6-AB1A-A1A936567E58Q35887719-4F0ABEB1-8ABE-4B27-BF4A-DF2782D129E9Q36104288-DB062D27-E39D-4EAA-BFBD-8E21533729B2Q36549805-546F3370-7B1F-41BD-8009-8B479307CC8FQ37180035-097A0EEC-752B-4A5A-B7FC-4512DC3DDA87Q37271640-17E5597F-6EF2-4CD3-9C76-80B964BEE409Q37313166-DA20076C-E9BF-4900-AB19-FC3B4B612C02Q37432074-50858CCF-C17D-46A5-802E-78248E341637Q37503337-DC232558-1DAD-4C7E-B19C-BFAFA81ACC13Q37519635-4080C233-F913-42EE-B20A-301C003BD55E
P2860
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Antiviral activity of telaprev ...... in patients with hepatitis C.
@en
Antiviral activity of telaprevir
@nl
type
label
Antiviral activity of telaprev ...... in patients with hepatitis C.
@en
Antiviral activity of telaprevir
@nl
prefLabel
Antiviral activity of telaprev ...... in patients with hepatitis C.
@en
Antiviral activity of telaprevir
@nl
P2093
P356
P1433
P1476
Antiviral activity of telaprev ...... in patients with hepatitis C.
@en
P2093
Christine J Weegink
Hendrik W Reesink
Hui-May Chu
Lindsay McNair
Nicole Forestier
Peter L M Jansen
Susan Purdy
Tara L Kieffer
P304
P356
10.1002/HEP.21774
P407
P577
2007-09-01T00:00:00Z